The heavily pretreated bladder cancer data suggest the cocktail can hold its own against a combination of rival drugs from Incyte and Merck.

Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.

Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial.

AstraZeneca and Amgen’s tezepelumab missed the primary endpoint in a phase 2a atopic dermatitis trial, raising doubts about its prospects.

Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”

FDA Commissioner Scott Gottlieb has hit back at plans that could see the Pentagon take control over the approval of some experimental drugs and devices for…

We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.

Amgen is laying off 200 people across its R&D organization, with sites in California bearing the brunt of the cuts.